Inhibition of cyclin-dependent kinases 4/6 (CDK4/6) has been shown in preclinical work to slow neuroblastoma cell growth [43] and several trials are now exploring this strategy for patients with relapsed disease, including in combination with dintuximab, temodar, irinotecan, and GMCSF (NCT04238819, NCT05429502, NCT03709680). The gene discussed is CDK4; the disease is neuroblastoma.